BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS to Treat Parkinson's Disease - Seite 3

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission. 

Contacts:   

BrainsWay: 
Ido Marom 
Chief Financial Officer 
844-386-7001 ext. 5
[e-mail] 

Investors: 
Brian Ritchie
LifeSci Advisors
646-889-1200
[e-mail]

Media Contact:
Chris Boyer
844-386-7001
[e-mail]